Solid Biosciences Inc.

XNASHealth care

Last traded price · USD

$6.41

−1.69%Delayed · Pre-market

Delayed 15 minutes · Source: ViewTrade · 5 Nov 2026, 15:05 IST · A quote does not mean the product is available to trade on your account.

Day's open: —
Previous close: $6.52
Volume: 172
Day's high: —
Day's low: —

In brief

Solid Biosciences Inc. is a health care company listed on Nasdaq, valued at about $687M.
Its shares closed at $6.52 on 4 Nov 2026, up 48.0% over the past year.
From India you can buy SLDB in US dollars under the RBI's Liberalised Remittance Scheme, including a fraction of one share. See what it costs

Questions investors ask

Can I buy Solid Biosciences Inc. (SLDB) shares from India?

Yes. Indian residents can invest in the US stock market under the Reserve Bank of India's Liberalised Remittance Scheme (LRS), which lets a resident individual remit up to USD 250,000 per financial year, across all permitted purposes combined. US-listed stocks and ETFs are a permitted investment under the LRS. You are solely responsible for ensuring your remittances comply with the LRS annual limit, the applicable Tax Collected at Source (TCS) rules, and all reporting requirements, including Schedule FA in your income-tax return.

Do I need the price of a whole SLDB share to invest?

Yes. You can buy fractional shares, which lets you invest a fixed rupee/dollar amount even in high-priced stocks. For example, if one share trades at USD 1,000 and you invest USD 100, you receive 0.1 of a share.

How much can I invest in US stocks in a year?

Under the LRS, an Indian resident can remit up to USD 250,000 per financial year (April to March) across all permitted purposes combined, from their own funds. This is a per-individual limit set by the RBI.

Can I trade SLDB options or futures?

No. Under RBI / FEMA rules, the LRS does not permit margin trading or speculative instruments such as futures, options, or other derivatives. Your US account is a cash account, not a derivatives and margin account.

Insights

Quotes run fifteen minutes behind.

Ahead of SPY and its sector fund XLV over 1 year
1 month: −5.8% (SPY −1.6%, XLV +13.5%). 3 months: −25.3% (SPY −0.4%, XLV +15.5%). 1 year: +48.0% (SPY +13.6%, XLV +30.7%). Price change to the 4 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: SLDB, SPY and XLV · as of 4 Nov 2026
8.5 days to cover short interest
12.3M shares were sold short at the 15 Oct 2026 settlement, 11.5% of the 107.2M shares outstanding; covering them would take 8.5 days of average volume. Short interest is reported twice a month, on a lag.
Exchange short-interest filing · as of 15 Oct 2026
Below its 50- and 200-day averages
The 4 Nov 2026 close of $6.52 was 14.5% below its 50-day average ($7.62) and 15.0% below its 200-day average ($7.67). It has closed below the 200-day for 30 sessions, since 24 Sep 2026. The 50-day average crossed below the 200-day on 4 Nov 2026, in the latest session.
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 4 Nov 2026
36% of the way up its 52-week range
Closed at $6.52 on 4 Nov 2026: 43.1% below the 52-week high of $11.45 (6 Jul 2026) and 72.0% above the low of $3.79 (7 Nov 2025).
Daily price bars, split-adjusted · as of 4 Nov 2026

Returns

Price return, split-adjusted

At the 4 Nov 2026 close

1 month−5.8%

6 months−9.4%

1 year+48.0%

5 years−82.3%

Newswire

About

Solid Biosciences Inc is a life sciences company focused on advancing a portfolio of current and future gene therapy candidates, including SGT-003 for the treatment of Duchenne muscular dystrophy, SGT-212 for the treatment of Friedreich's ataxia, SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia, SGT-601 for the treatment of TNNT2-mediated dilated cardiomyopathy, and additional assets for the treatment of genetic cardiac and neuromuscular diseases. The majority of its current programs are designed to treat these diseases with gene transfer products. The company operates in a single segment, developing treatments through gene therapy and other means for patients with neuromuscular and cardiac diseases.

Website

Notable moves

January 9, 2024
+35.29%
December 7, 2023
+68.42%
March 11, 2022
+37.38%

Newswire

About

Website

Notable moves

January 9, 2024
+35.29%
December 7, 2023
+68.42%
March 11, 2022
+37.38%

Solid Biosciences Inc.

XNASHealth care

Last traded price · USD

$6.41

−1.69%Delayed · Pre-market

Delayed 15 minutes · Source: ViewTrade · 5 Nov 2026, 15:05 IST · A quote does not mean the product is available to trade on your account.

Day's open: —
Previous close: $6.52
Volume: 172
Day's high: —
Day's low: —

In brief

Solid Biosciences Inc. is a health care company listed on Nasdaq, valued at about $687M.
Its shares closed at $6.52 on 4 Nov 2026, up 48.0% over the past year.
From India you can buy SLDB in US dollars under the RBI's Liberalised Remittance Scheme, including a fraction of one share. See what it costs

Questions investors ask

Can I buy Solid Biosciences Inc. (SLDB) shares from India?

Do I need the price of a whole SLDB share to invest?

How much can I invest in US stocks in a year?

Can I trade SLDB options or futures?

Insights

Quotes run fifteen minutes behind.

Ahead of SPY and its sector fund XLV over 1 year
1 month: −5.8% (SPY −1.6%, XLV +13.5%). 3 months: −25.3% (SPY −0.4%, XLV +15.5%). 1 year: +48.0% (SPY +13.6%, XLV +30.7%). Price change to the 4 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: SLDB, SPY and XLV · as of 4 Nov 2026
8.5 days to cover short interest
12.3M shares were sold short at the 15 Oct 2026 settlement, 11.5% of the 107.2M shares outstanding; covering them would take 8.5 days of average volume. Short interest is reported twice a month, on a lag.
Exchange short-interest filing · as of 15 Oct 2026
Below its 50- and 200-day averages
The 4 Nov 2026 close of $6.52 was 14.5% below its 50-day average ($7.62) and 15.0% below its 200-day average ($7.67). It has closed below the 200-day for 30 sessions, since 24 Sep 2026. The 50-day average crossed below the 200-day on 4 Nov 2026, in the latest session.
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 4 Nov 2026
36% of the way up its 52-week range
Closed at $6.52 on 4 Nov 2026: 43.1% below the 52-week high of $11.45 (6 Jul 2026) and 72.0% above the low of $3.79 (7 Nov 2025).
Daily price bars, split-adjusted · as of 4 Nov 2026

Returns

Price return, split-adjusted

At the 4 Nov 2026 close

1 month−5.8%

6 months−9.4%

1 year+48.0%

5 years−82.3%

Newswire

About

Website

Notable moves

January 9, 2024
+35.29%
December 7, 2023
+68.42%
March 11, 2022
+37.38%

Newswire

About

Website

Notable moves

January 9, 2024
+35.29%
December 7, 2023
+68.42%
March 11, 2022
+37.38%

Solid Biosciences Inc.

Solid Biosciences Inc. in brief

Ahead of SPY and its sector fund XLV over 1 year

8.5 days to cover short interest

Below its 50- and 200-day averages

36% of the way up its 52-week range

Solid Biosciences Inc.

Solid Biosciences Inc. in brief

Ahead of SPY and its sector fund XLV over 1 year

8.5 days to cover short interest

Below its 50- and 200-day averages

36% of the way up its 52-week range